Feeds:
Posts
Comments

Search Results for 'PCSK9'

Injectable inclisiran (siRNA) as 3rd anti-PCSK9 behind mAbs Repatha and Praluent Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 4/27/2021 Combining AstraZeneca’s ‘good’ cholesterol booster with PCSK9 inhibition shows promise in heart disease by Angus Liu | Apr 21, 2021 3:00pm The drug, dubbed MEDI5884, is designed to neutralize a circulating enzyme called endothelial lipase. The protein regulates […]

Read Full Post »

 Cholesterol Lowering Novel PCSK9 drugs: Praluent [Sanofi and Regeneron] vs Repatha [Amgen] – which drug cuts CV risks enough to make it cost-effective? Reporter: Aviva Lev-Ari, PhD, RN   UPDATED on 4/5/2022 Early PCSK9 Inhibition in AMI Yields Plaque Regression Ted Bosworth April 05, 2022 https://www.medscape.com/viewarticle/971582?spon=2&uac=93761AJ&impID=4140595&sso=true&faf=1&src=WNL_mdpls_220405_mscpedit_card https://www.mdedge.com/cardiology/article/253443/lipid-disorders/early-pcsk9-inhibition-ami-yields-plaque-regression   UPDATED on 1/15/2019 In the patent fight over PCSK9 inhibitors, […]

Read Full Post »

Cholesterol-busting gut bacteria affect people’s cardiac health Reporter: Irina Robu, PhD Scientists at Broad Institute of MIT and Harvard University, has discovered a group a gut bacterium that can metabolize enough cholesterol to affect metabolism. Their study in Cell Host and Microbe, found that bacteria in the intestines have lower cholesterol levels in their blood. […]

Read Full Post »

ODYSSEY Outcomes trial evaluating the effects of a PCSK9 inhibitor, alirocumab, on major cardiovascular events in patients with an acute coronary syndrome to be presented at the American College of Cardiology meeting on March 10. Reporter: Aviva Lev-Ari, PhD, RN   For PCSK9 inhibitors, the effect on major adverse cardiovascular events has always fallen short of expectations based on […]

Read Full Post »

FDA approval on 12/1/2017 of Amgen’s evolocumb (Repatha) a PCSK9 inhibitor for the prevention of heart attacks, strokes, and coronary revascularizations in patients with established cardiovascular disease Reporter: Aviva Lev-Ari, PhD, RN   Evolocumab was first FDA approved in 2015 for patients with familial hypercholesterolemia and others who fail to achieve LDL cholesterol lowering through diet and […]

Read Full Post »

19 of the 49 New Therapeutic Molecular Entities FDA approved in 2020 — as well as a new Cell-based therapy — are Personalized Medicines Reporter: Aviva Lev-Ari, PhD, RN   2020 DRUG APPROVALS 19 of the 49 new therapeutic molecular entities FDA approved in 2020 — as well as a new cell-based therapy — are […]

Read Full Post »

Reversing Heart Disease: Combination of PCSK9 Inhibitors and Statins – Opinion by Steven Nissen, MD, Chairman of Cardiovascular Medicine at Cleveland Clinic Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 2/25/2019 https://www.medpagetoday.com/cardiology/prevention/78202?xid=nl_mpt_SRCardiology_2019-02-25&eun=g99985d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=CardioUpdate_022519&utm_term=NL_Spec_Cardiology_Update_Active While nearly 10% of middle-age adults in China have high risk for cardiovascular disease, only 0.6% of these high-risk individuals use statins and 2.4% […]

Read Full Post »

Original Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases NEW GENRE Volume Five: Pharmacological Agents in Treatment of Cardiovascular Diseases https://pharmaceuticalintelligence.com/audio-english-spanish-biomed-e-series/new-genre-audio-english-spanish-series-a-e-books-on-cardiovascular-diseases/new-genre-volume-five-pharmacological-agents-in-treatment-of-cardiovascular-diseases-series-a-volume-5/ This volume has the following three parts: PART A: The eTOCs in Spanish in Audio format PART B: The eTOCs in Bi-lingual format: Spanish and English in Text format PART C: The Editorials of the original e-Books in […]

Read Full Post »

eProceedings – Day 1: Charles River Laboratories – 3rd World Congress, Delivering Therapies to the Clinic Faster, September 23 – 24, 2019, 25 Edwin H. Land Boulevard, Cambridge, MA   https://events.criver.com/event/9eab0ee1-982e-42c6-a4cd-fb43f9f2f1d0/confirmation:7c68cf9b-c599-469e-b602-42178c77e4f9   ANNOUNCEMENT   Leaders in Pharmaceutical Business Intelligence (LPBI) Group will cover this event in Real Time for pharmaceuticalintelligence.com  Confirmation Number: 8ZNCBYNGHCK In attendance […]

Read Full Post »

A new mechanism of action to attack in the treatment of coronary artery disease (CAD), Novartis developed Ilaris (canakinumab), a human monoclonal antibody targeting the interleukin-1beta innate immunity pathway Reporter: Aviva Lev-Ari, PhD, RN   Speaking at an ESC press briefing, Ridker said, “This is what personalized predictive medicine is all about.” Once a patient has […]

Read Full Post »

Next »

%d bloggers like this: